Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 9/20 | 0.43 |
| ▸ | CA2 | P00918 | 9/20 | 0.43 |
| ▸ | TLR7 | Q9NYK1 | 4/20 | 0.40 |
| ▸ | CA12 | O43570 | 5/20 | 0.39 |
| ▸ | CA9 | Q16790 | 5/20 | 0.39 |
| ▸ | STK17B | O94768 | 1/20 | 0.38 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14383622 | 0.86 | CDK1 (0.47) | CA1CA2TLR7KDM4EMAPT | |
| SCHEMBL14383623 | 0.82 | HDAC8 (0.41) | CA1CA2TLR7KDM4EL3MBTL1 | |
| SCHEMBL2097346 | 0.82 | PIN1 (0.47) | CA1CA2TLR7KDM4EMAPT | |
| SCHEMBL2056440 | 0.70 | CA1 (0.43) | CA1CA2TLR7CA12CA9 | |
| SCHEMBL31245919 | 0.66 | CA1 (0.67) | CA1CA2CA12CA9CYP3A4 | |
| SCHEMBL1370043 | 0.66 | CA1 (0.49) | CA1CA2CA12CA9STK17B | |
| SCHEMBL13480197 | 0.66 | TDP1 (0.58) | CA1CA2CA12CA9L3MBTL1 | |
| SCHEMBL12968430 | 0.66 | CA1 (0.51) | CA1CA2TLR7CA12CA9 | |
| SCHEMBL12968433 | 0.66 | CA1 (0.51) | CA1CA2TLR7CA12CA9 | |
| SCHEMBL15613905 | 0.64 | CA12 (0.54) | CA1CA2CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1730298-B1 | SPECIFIC SUBSTRATES FOR O6-ALKYLGUANINE-DNA ALKYLTRANSFERASE | EPFL ECOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE (CH) | 2015-11-11 | — | — | EP | disclosed |
| US-8163479-B2 | Specific substrates for O6-alkylguanine-DNA alkyltransferase | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (CH) | 2012-04-24 | — | — | US | disclosed |
| US-20070243568-A1 | Specific Substrates for O6-Alkylguanine-Dna Alkyltransferase | EPFL ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (CH) | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070243568-A1 | Specific Substrates for O6-Alkylguanine-Dna Alkyltransferase | AGT, AGXT, AGTR1 | CA1 4500/4885CA2 3221/4885TLR7 3143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.